Shenzhen Salubris Pharmaceuticals Co Ltd operates within the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Shenzhen Salubris Pharmaceuticals Co Ltd with three other
companies in this sector in China:
Tianjin Chase Sun Pharmaceutical Company Limited
sales of 3.87 billion Chinese Renmimbi [US$567.02 million]
of which 49%
Shijiazhuang Yiling Pharmaceutical Co Ltd
(3.82 billion Chinese Renmimbi [US$560.13 million]
of which 100%
was Medicine), and
JiangSu Bicon Pharmaceutical Listed Co
(3.72 billion Chinese Renmimbi [US$546.02 million]
of which 65%
was Pharmaceutical Intermediates).
During the year ended December of 2016, sales at
Shenzhen Salubris Pharmaceuticals Co Ltd were 3.83 billion Chinese Renmimbi (US$562.10 million).
increase of 10.2%
versus 2015, when the company's sales were 3.48 billion Chinese Renmimbi.
This was the fifth consecutive year of sales increases at Shenzhen Salubris Pharmaceuticals Co Ltd
(and since 2011, sales have increased a total of 160%).